In a report released yesterday, Mani Foroohar from SVB Securities maintained a Buy rating on AlloVir (ALVR – Research Report). The company’s shares opened today at $4.25.
According to TipRanks, Foroohar is an analyst with an average return of -11.8% and a 41.70% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.
Currently, the analyst consensus on AlloVir is a Strong Buy with an average price target of $23.00, representing a 441.18% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $10.29 and a one-year low of $3.17. Currently, AlloVir has an average volume of 283.2K.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALVR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
